MedTrace Logo

Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults

NCT02238756 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-06-06

No results posted yet for this study

Summary

The purpose of this clinical trial is to investigate the safety and tolerability of IM administered CV8102 and an IM administered combination of CV8102 and rabies vaccine in humans.

Conditions

  • Rabies

Interventions

BIOLOGICAL

CV8102

Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart

BIOLOGICAL

Rabipur

Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart

BIOLOGICAL

CV8102 + Rabipur

Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Principal Investigators

  • Ingo Meyer, MD · CRS Clinical Research Services Mönchengladbach GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-09-30
Completion
2016-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02238756 on ClinicalTrials.gov